"Melanoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
Descriptor ID |
D008545
|
MeSH Number(s) |
C04.557.465.625.650.510 C04.557.580.625.650.510 C04.557.665.510
|
Concept/Terms |
Melanoma- Melanoma
- Melanomas
- Malignant Melanoma
- Malignant Melanomas
- Melanoma, Malignant
- Melanomas, Malignant
|
Below are MeSH descriptors whose meaning is more general than "Melanoma".
Below are MeSH descriptors whose meaning is more specific than "Melanoma".
This graph shows the total number of publications written about "Melanoma" by people in this website by year, and whether "Melanoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 4 | 1 | 5 |
1996 | 11 | 2 | 13 |
1997 | 8 | 0 | 8 |
1998 | 10 | 0 | 10 |
1999 | 9 | 1 | 10 |
2000 | 14 | 1 | 15 |
2001 | 13 | 3 | 16 |
2002 | 16 | 3 | 19 |
2003 | 14 | 2 | 16 |
2004 | 13 | 2 | 15 |
2005 | 9 | 1 | 10 |
2006 | 22 | 2 | 24 |
2007 | 20 | 1 | 21 |
2008 | 25 | 4 | 29 |
2009 | 22 | 3 | 25 |
2010 | 18 | 5 | 23 |
2011 | 36 | 4 | 40 |
2012 | 27 | 2 | 29 |
2013 | 27 | 6 | 33 |
2014 | 30 | 4 | 34 |
2015 | 31 | 0 | 31 |
2016 | 19 | 0 | 19 |
2017 | 45 | 0 | 45 |
2018 | 24 | 1 | 25 |
2019 | 36 | 0 | 36 |
2020 | 37 | 5 | 42 |
2021 | 27 | 1 | 28 |
2022 | 31 | 0 | 31 |
2023 | 30 | 0 | 30 |
2024 | 25 | 3 | 28 |
2025 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Melanoma" by people in Profiles.
-
Transcriptomic signatures in peripheral CD4+T-lymphocytes may reflect melanoma staging and immunotherapy responsiveness prior to ICI initiation. Front Immunol. 2025; 16:1529707.
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025 May 02; 220:115381.
-
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76?K trial. Eur J Cancer. 2025 May 02; 220:115371.
-
The potential impact of ACOG guideline changes on genital melanoma detection rates in females: a retrospective cross-sectional analysis and implications for clinical practice. Arch Dermatol Res. 2025 Feb 19; 317(1):438.
-
Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma. J Immunother Cancer. 2025 Feb 12; 13(2).
-
Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2025 Apr; 43(10):1219-1228.
-
Causal models and prediction in cell line perturbation experiments. BMC Bioinformatics. 2025 Jan 07; 26(1):4.
-
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial. Nat Med. 2025 Jan; 31(1):144-151.
-
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204. J Clin Oncol. 2025 Apr; 43(10):1210-1218.
-
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047. J Clin Oncol. 2025 May; 43(13):1546-1552.